Science Explorer Back to mapMap
Discussion
Institution · Apollomics (United States)

Most cited papers from Apollomics (United States)

Apollomics (United States)

What are the most cited papers from Apollomics (United States)?

The most cited paper from Apollomics (United States) is "Mass Spectrometry-based Solutions for Single-cell Proteomics" (Siqi Li, Shuwei Li, Siqi Liu et al., 2025), with 10 citations. Next come "Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements" (7) and "Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor" (3).

Showing 8 of 8 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Mass Spectrometry-based Solutions for Single-cell Proteomics Siqi Li, Shuwei Li, Siqi Liu et al. · Genomics Proteomics & Bioinformatics Open access Feb 2025 10
2 Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements Seshiru Nakazawa et al. · Cancer Discovery 9 Apr 2025 7
3 Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor Sani Haider Kizilbash, A. El-Khoueiry, Richard Lerner et al. · European Journal of Cancer Open access Oct 2020 3
4 1382P Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations Maurice Pérol, Mark Magdi Awad, Siddhartha H. K. Devarakonda et al. · Annals of Oncology Open access Sep 2024 1
5 Enrichment of glycoRNAs using galactose oxidase, hydrazide chemistry, and glycosidase digestion Xinyu Miao, Jianbo Deng, Xiaotong Wang et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 2 Jun 2024 0
6 P2.09-41 Phase I/II Study Exploring Safety and Efficacy of Apl-101 Plus Frontline Osimertinib in EGFR-mutated Metastatic Non-small Cell Lung Cancer Bijal Manish Patel, Ningying Wu, S. Terence Myles et al. · Journal of Thoracic Oncology Open access 31 Oct 2023 0
7 MET/HGF Coexpression as a Novel Predictive Biomarker for Response to MET Inhibitor Therapy in a Case of Psammomatous Melanotic Schwannoma Jing Li, Xiaoling Zhang, Neil Sankar et al. · JCO Precision Oncology Jun 2022 0
8 TRLS-06. A Phase 1–2 clinical trial of EO1001 (APL-122), a novel irreversible pan-ErbB inhibitor with promising brain penetration Sophia Frentzas, Gary Edward Richardson, Jeffrey Bacha et al. · Neuro-Oncology Advances Open access Aug 2021 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.